Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.36 |
| ▸ | HTR1A | P08908 | 9/20 | 0.34 |
| ▸ | DRD2 | P14416 | 9/20 | 0.34 |
| ▸ | HTR2A | P28223 | 5/20 | 0.34 |
| ▸ | HTR2C | P28335 | 5/20 | 0.34 |
| ▸ | HTR2B | P41595 | 5/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6862505 | 0.99 | CA2 (0.35) | CA2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL6860665 | 0.78 | DRD2 (0.53) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6322438 | 0.78 | DRD2 (0.41) | CA2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL6855950 | 0.78 | DRD2 (0.39) | CA2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL6862882 | 0.75 | LMNA (0.40) | CA2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL6861792 | 0.75 | LMNA (0.40) | CA2HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL6861375 | 0.74 | ALDH1A1 (0.61) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6862467 | 0.73 | KDM4E (0.40) | DRD2HTR2A | |
| SCHEMBL6199543 | 0.70 | HTR1A (0.36) | CA2HTR1ADRD2 | |
| SCHEMBL6774282 | 0.70 | HTR1A (0.32) | CA2HTR1ADRD2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800648-B2 | SCHIZOPHRENIA, BIPOLAR DISORDERS, PARKINSON'S DISEASE; DRUG ABRUSE | WYETH | 2004-10-05 | — | — | US | claimed |
| US-20030073697-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one | WYETH | 2003-04-17 | — | — | US | claimed |
| WO-2002088142-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[a]NAPHTHALEN-2-ONE | WYETH (US) | 2002-11-07 | — | — | WO | claimed |
| US-6800648-B2 | SCHIZOPHRENIA, BIPOLAR DISORDERS, PARKINSON'S DISEASE; DRUG ABRUSE | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20030073697-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one | WYETH | 2003-04-17 | — | — | US | disclosed |
| WO-2002088142-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[a]NAPHTHALEN-2-ONE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073697-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one | SNCA, TUBA1C, SLC6A3 | CA2 4498/4885HTR1A 20/4885DRD2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.